CVS Group engages CMA on UK veterinary services probe

Published 10/06/2025, 08:58
CVS Group engages CMA on UK veterinary services probe

LONDON - CVS Group plc, a leading provider of veterinary services, has acknowledged the Competition and Markets Authority’s (CMA) decision to extend the statutory deadline for its investigation into the UK veterinary services market. The extension will allow the CMA to fully consider industry feedback on proposed remedies aimed at increasing transparency in the supply of veterinary services for household pets.

The company has been actively participating in discussions with the CMA, advocating for transparency measures that address the regulator’s concerns without imposing undue burdens on veterinary practices or compromising animal welfare. CVS has expressed support for the CMA’s focus on improving communication and transparency but has cautioned against remedies that could restrict veterinarians’ clinical independence.

CVS Group CEO Richard Fairman conveyed optimism that the extended period for review would result in a balanced and proportionate remedy package. However, he also recognized the impact of the ongoing uncertainty on CVS employees and other stakeholders, promising continued support throughout the extended review process.

The CMA’s market review, which began on September 7, 2023, has involved CVS Group since its inception. The company, which operates approximately 460 veterinary practices and employs about 9,000 personnel, including around 2,400 veterinary surgeons, has been a collaborative partner in the review.

The extension granted by the CMA aims to ensure that any interventions are carefully considered and that their implications for the veterinary industry and pet owners are thoroughly understood. CVS Group’s engagement with the CMA reflects its commitment to maintaining high standards of animal care while also addressing the regulatory concerns.

The information presented in this article is based on a press release statement from CVS Group plc.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.